Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: A case report
- 31 January 2022
- journal article
- research article
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (6) , 810-813
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- COVID-19 Recovery Without B Cells or Antibodies in Patients Receiving Rituximab for Autoimmune Disease2021
- Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patientJournal of Infection and Chemotherapy, 2021
- Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for CancerNew England Journal of Medicine, 2020
- Characteristics and outcomes of coronavirus disease 2019 (COVID-19) patients with cancer: a single-center retrospective observational study in Tokyo, JapanInternational Journal of Clinical Oncology, 2020
- Severe organising pneumonia following COVID-19Thorax, 2020
- Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort studyeClinicalMedicine, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in SingaporeJAMA, 2020
- Kinetics of T‐cell subset reconstitution following treatment with bendamustine and rituximab for low‐grade lymphoproliferative disease: a population‐based analysisBritish Journal of Haematology, 2018
- Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune diseaseJournal of Autoimmunity, 2015